Work

936P A phase I dose escalation trial of IKS014, a HER2-targeting antibody drug conjugate (ADC), in participants with advanced HER2+ solid tumors

Year: 2025

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.08.1505

Authors: M. Ameratunga, A. Nagrial, P.K.H. Lau, K.T. Bui, D. Sabanathan, D.M. Browning, J. Thirlway, R.J. Lutz, J. Deckert, J. O'Leary, V. Ganju

Institutions: The Alfred Hospital, Alfred Health, Westmead Hospital, Linear Clinical Research, Macquarie University

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415942072

FWCI:

Cites:

Cited by:

Related to: 10